Richard Kent, M.D.
Rick joined Intersouth Partners in 2008, having previously served as President & CEO of Serenex, Inc., an Intersouth portfolio company that was acquired by Pfizer in April 2008. At Serenex, he managed and grew the company from an early-stage drug discovery company, ultimately directing the company's acquisition. Prior to his work at Serenex, he served as CEO of Ardent Pharmaceuticals, another venture-backed start-up company. He served as Senior Vice President, Global Medical Affairs and Chief Medical Officer for GlaxoSmithKline, and held other senior positions within GlaxoWellcome and Burroughs Wellcome.
In these positions, he supervised dozens of INDs and more than 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular and Oncology.
Rick received his undergraduate degree from the University of Carlifornia, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University's medical faculty. He is board certified in both internal medicine and cardiology.